CD274 and head and neck squamous cell carcinoma: Studies of PD-L1 (also known as CD274) expression in CSCs have yielded contradictory results in HNSCC [42], indicating that CSCs targeted with anti-PD/PD-L1 antibodies may not be as affected as thought, and other immune checkpoints can be involved.